Qin W, Liu Z, Huang M, Liang L, Gan Y, Huang Z
Int J Mol Sci. 2025; 26(4).
PMID: 40003893
PMC: 11855556.
DOI: 10.3390/ijms26041425.
van Wier S, Beekman A
Chem Soc Rev. 2025; 54(4):1684-1698.
PMID: 39817557
PMC: 11736853.
DOI: 10.1039/d4cs00243a.
Tsukamoto S, Huaze Y, Weisheng Z, Machinaga A, Kakiuchi N, Ogawa S
Cancer Sci. 2024; 116(3):724-735.
PMID: 39731327
PMC: 11875792.
DOI: 10.1111/cas.16439.
Ghadrdoost Nakhchi B, Kosuru R, Chrzanowska M
Int J Mol Sci. 2024; 25(18).
PMID: 39337337
PMC: 11432579.
DOI: 10.3390/ijms25189853.
Wang J, Botvinov J, Bhatt A, Beyer K, Kreis M, Adam M
Cells. 2024; 13(8.
PMID: 38667294
PMC: 11049420.
DOI: 10.3390/cells13080679.
From bench to bedside: current development and emerging trend of KRAS-targeted therapy.
Chen Y, Liu Q, Xie H, Ding J
Acta Pharmacol Sin. 2023; 45(4):686-703.
PMID: 38049578
PMC: 10943119.
DOI: 10.1038/s41401-023-01194-4.
Design of Protein Segments and Peptides for Binding to Protein Targets.
Gupta S, Azadvari N, Hosseinzadeh P
Biodes Res. 2023; 2022:9783197.
PMID: 37850124
PMC: 10521657.
DOI: 10.34133/2022/9783197.
Exploring Covalent Bond Formation at Tyr-82 for Inhibition of Ral GTPase Activation.
Landgraf A, Yeh I, Ghozayel M, Bum-Erdene K, Gonzalez-Gutierrez G, Meroueh S
ChemMedChem. 2023; 18(16):e202300272.
PMID: 37269475
PMC: 10529880.
DOI: 10.1002/cmdc.202300272.
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS.
Yin G, Huang J, Petela J, Jiang H, Zhang Y, Gong S
Signal Transduct Target Ther. 2023; 8(1):212.
PMID: 37221195
PMC: 10205766.
DOI: 10.1038/s41392-023-01441-4.
Targeting Protein-Protein Interfaces with Peptides: The Contribution of Chemical Combinatorial Peptide Library Approaches.
Monti A, Vitagliano L, Caporale A, Ruvo M, Doti N
Int J Mol Sci. 2023; 24(9).
PMID: 37175549
PMC: 10178479.
DOI: 10.3390/ijms24097842.
KRAS Inhibitor that Simultaneously Inhibits Nucleotide Exchange Activity and Effector Engagement.
Pagba C, Gupta A, Naji A, van der Hoeven D, Churion K, Liang X
ACS Bio Med Chem Au. 2023; 2(6):617-626.
PMID: 37101428
PMC: 10125367.
DOI: 10.1021/acsbiomedchemau.2c00045.
Targeting the 'Undruggable' Driver Protein, KRAS, in Epithelial Cancers: Current Perspective.
Lam K, Wong S, Cheah P
Cells. 2023; 12(4).
PMID: 36831298
PMC: 9954350.
DOI: 10.3390/cells12040631.
Controlling oncogenic KRAS signaling pathways with a Palladium-responsive peptide.
Learte-Aymami S, Martin-Malpartida P, Roldan-Martin L, Sciortino G, Couceiro J, Marechal J
Commun Chem. 2023; 5(1):75.
PMID: 36697641
PMC: 9814687.
DOI: 10.1038/s42004-022-00691-7.
A glutamine-based single α-helix scaffold to target globular proteins.
Escobedo A, Piccirillo J, Aranda J, Diercks T, Mateos B, Garcia-Cabau C
Nat Commun. 2022; 13(1):7073.
PMID: 36400768
PMC: 9674830.
DOI: 10.1038/s41467-022-34793-6.
Targeting RAS mutants in malignancies: successes, failures, and reasons for hope.
Yang H, Zhou X, Fu D, Le C, Wang J, Zhou Q
Cancer Commun (Lond). 2022; 43(1):42-74.
PMID: 36316602
PMC: 9859734.
DOI: 10.1002/cac2.12377.
Peptide-based covalent inhibitors of protein-protein interactions.
Paulussen F, Grossmann T
J Pept Sci. 2022; 29(1):e3457.
PMID: 36239115
PMC: 10077911.
DOI: 10.1002/psc.3457.
KRAS as a Key Oncogene in the Clinical Precision Diagnosis and Treatment of Pancreatic Cancer.
Dai M, Chen S, Teng X, Chen K, Cheng W
J Cancer. 2022; 13(11):3209-3220.
PMID: 36118526
PMC: 9475360.
DOI: 10.7150/jca.76695.
Chemical acylation of an acquired serine suppresses oncogenic signaling of K-Ras(G12S).
Zhang Z, Guiley K, Shokat K
Nat Chem Biol. 2022; 18(11):1177-1183.
PMID: 35864332
PMC: 9596369.
DOI: 10.1038/s41589-022-01065-9.
Targeting the "undruggable" RAS - new strategies - new hope?.
Morchen B, Shkura O, Stoll R, Helfrich I
Cancer Drug Resist. 2022; 2(3):813-826.
PMID: 35582595
PMC: 8992515.
DOI: 10.20517/cdr.2019.21.
Targeting the "undruggable" RAS with biologics.
Whaby M, Khan I, OBryan J
Adv Cancer Res. 2022; 153:237-266.
PMID: 35101232
PMC: 9627686.
DOI: 10.1016/bs.acr.2021.07.006.